Buying Time

Geographic atrophy used to be a disease retina specialists watched. The approval of two complement inhibitors changed that, and the hard part turned out not to be the injection. It is the conversation. In this iD Social roundtable, Murtaza Adam, MD (Colorado Retina Associates, Denver) moderates a discussion with Ferhina Ali, MD (retina specialist, New York) and Seenu Hariprasad, MD (Chair of Ophthalmology, University of Chicago) on how they treat GA in practice: who is a candidate, when to start, how to explain a benefit the patient cannot see, and what it takes to keep patients on therapy past the month-six wall. Topics 0:00 Introduction A disease we used to watch: how the approvals changed practice Who to treat and when to start Setting expectations when the patient cannot see the benefit Treatment fatigue, persistence and the month six to ten drop-off Patient assistance and access Educating the referral base: the patients who never reach us How to frame GA treatment today Panel Murtaza Adam, MD, Colorado Retina Associates, Denver (moderator) Ferhina Ali, MD, Retina Specialist, New York Seenu Hariprasad, MD, University of Chicago GA in Practice is an iD Social roundtable series. This program is editorially independent and was produced with support from Astellas. The views expressed are those of the participating physicians. For healthcare professionals.